Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Cannalean Biotechs
Cannalean Biotechs Overview
CannaLean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan that can potentially benefit millions of patients with dyslipidemia.
CannaLean uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. The company's preliminary results show the effect of the formulation on cholesterol and triglyceride reduction.
A provisional patent was filed in 2017 by Mor Research Applications, the technology transfer unit of Clalit Health Services. The patent covers a composition of CBD and chitosan for improving dyslipidemia and other signs and symptoms of metabolic syndrome.
CannaLean Biotechs was established in partnership with Mor Research Applications.